Protective effect of inactivated bovine herpesvirus-1 in calves experimentally infected with bovine herpesvirus-1 and Pasteurella haemolytica.
The protective effect of an inactivated whole-virion bovine herpesvirus-1 (BHV-1) immunising inoculum, without adjuvant, against viral-bacterial respiratory disease was studied in three experimental treatment groups of five calves each. One group was boosted 14 days after the first vaccination and at this time the second group received their initial inoculation. Seven days later, calves were challenged with BHV-1 in aerosol and four days after this challenge all calves were exposed to Pasteurella haemolytica A1 in aerosol. Among the three groups, differences in rectal temperature responses four days after viral challenge (P less than 0.01) did not relate to protection. However the main response variable, viral-bacterial pneumonia, was reduced in boosted calves (P less than 0.05).
Pasteurella haemolytica serotype 1 colonization of the nasal passages of virus-infected calves.
Nasal passages of calves with a virus-induced respiratory tract disease became colonized by Pasteurella haemolytica serotype 1 after they were inoculated intranasally with P haemolytica. Inoculation with infectious bovine rhinotracheitis virus caused a more severe clinical illness and resulted in a greater degree of colonization with P haemolytica than developed after inoculation with parainfluenza-3 virus. Nasal passages of parainfluenza-3 virus-inoculated calves were colonized to a greater degree with P haemolytica than were those of healthy, nonstressed calves. Calves were susceptible to P haemolytica colonization during or shortly after virus-induced illness, even though they had been previously exposed to P haemolytica and had serum antibody and nasal secretion antibody to P haemolytica.
Hapten inhibition of passive antidextran dextran anaphylaxis in guinea pigs. Role of molecular size in anaphylactogenicity and precipitability of dextran fractions.
High titred antidextran antisera have been raised in rabbits by prolonged immunization with soluble conjugates between isomaltose oligosaccharides or dextran mw 4,400 and bovine serum albumin in complete Freund’s adjuvant. Guinea pigs sensitized with such antisera exhibited anaphylactic shock on i.v. challenge with fractions of hydrolyzed B512 dextran. The severity of anaphylaxis depended on the amount of sensitizing antibody and the dose and molecular size of the challenging dextran fraction. In maximally sensitized animals, fractions of mw 3,600 or larger were anaphylactogenic and smaller molecular size fractions were nonanaphylactogenic. In submaximally sensitized animals, dextran fractions of mw 10,500 or less were foundnonanaphylactogenic. In addition, nonanaphylactogenic dextran fractions produced desensitization, i.e. protection from anaphylaxis due to subsequent or simultaneous injection of more high molecular and anaphylactogenic dextran fractions. When the molar ratio in a mixture of nonanaphylactogenic/anaphylactogenic fractions was about 7.6, protection was complete with reduction of mortality from 100 to 0%. A molar ratio of 1.9, corresponding to a 13-percent by weight admixture of nonanaphylactogenic dextran, still significantly reduced mortality from 100 to 50%. From the ability to form precipitates with antidextrans and to elicit anaphylaxis in sensitized guinea pigs, and from the absence of these properties, the approximate molecular size range of bivalent and monovalent dextran B512 fractions was found to correspond to mw 3,600 and mw 1,430, respectively. The practical applicability of hapten inhibition is discussed.